- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View | 1 | Benzinga.com | ||
| 30.04. | Harmony Biosciences Holdings Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 30.04. | Key Takeaways From Harmony Biosciences Analyst Ratings | 1 | Benzinga.com | ||
| 30.04. | Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline | 2 | Seeking Alpha | ||
| 30.04. | Harmony Biosciences Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.04. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M | 1 | Seeking Alpha | ||
| 30.04. | Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy | 98 | GlobeNewswire (Europe) | WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half... ► Artikel lesen | |
| 30.04. | Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets | 80 | PR Newswire | Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations
EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026
Plan to Initiate Phase... ► Artikel lesen | |
| 29.04. | Harmony Biosciences Q1 2024 Earnings Preview | 1 | Seeking Alpha | ||
| 11.04. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.04. | Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist | 104 | PR Newswire | PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and... ► Artikel lesen | |
| 03.04. | Harmony Biosciences Initiates Global Phase 3 Registrational Trial (tempo Study) Of Pitolisant In Patients With Prader-willi Syndrome | 83 | PR Newswire | PLYMOUTH MEETING, Pa., April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate... ► Artikel lesen | |
| 28.03. | Evaluating Harmony Biosciences: Insights From 8 Financial Analysts | 1 | Benzinga.com | ||
| 19.03. | Harmony Biosciences exec sells over $383k in stock | 1 | Investing.com | ||
| 28.02. | Harmony Biosciences Holdings, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 23.02. | Earnings call: Harmony Biosciences reports 2023 growth driven by WAKIX | 1 | Investing.com | ||
| 22.02. | Harmony Biosciences Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.02. | Raymond James lifts Harmony Biosciences target on steady net patient adds | 2 | Investing.com | ||
| 22.02. | Analyst Ratings For Harmony Biosciences | 1 | Benzinga.com |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,600 | -2,74 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,900 | +0,71 % | CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss | ||
| MAINZ BIOMED | 0,619 | +0,32 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease Week 2024 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,924 | -4,35 % | Bayer auf dem Weg aus der Krise. Stehen auch Defence Therapeutics und BioNTech mit ihren Onkologie-Pipelines vor dem Turnaround? | Nach mehreren Jahren, in denen der Pharma- und Agrarchemiekonzern Bayer von einer Krise in die nächste stolperte, zeichnen sich nun Zeichen einer Erholung am Horizont ab. Während Bayer seinen langen... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,690 | -21,59 % | Ginkgo Bioworks Reports First Quarter 2024 Financial Results | Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026
Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 39,460 | -1,99 % | Halozyme Therapeutics, Inc.: Halozyme Reports First Quarter 2024 Financial And Operating Results | Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1
Royalty Revenue Increased 21% YOY... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,540 | 0,00 % | Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss | ||
| RECURSION PHARMACEUTICALS | 8,640 | 0,00 % | Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know | ||
| ARGENX | 353,50 | +0,28 % | argenx SE: argenx Reports First Quarter 2024 Financial Results and Provides Business Update | $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,140 | +1,79 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational Highlights | Pelareorep advancing to registration-enabling studies
Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer
Overall survival... ► Artikel lesen | |
| ARDELYX | 7,210 | -4,60 % | Ardelyx, Inc.: Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference | ||
| ASSERTIO | 1,045 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports First Quarter 2024 Financial Results | First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow from Operations Increases Cash to $80.7 Million... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,790 | 0,00 % | Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 7,745 | 0,00 % | SIGA Technologies, Inc. (SIGA) Q1 2024 Earnings Call Transcript | ||
| MERRIMACK PHARMACEUTICALS | 15,060 | 0,00 % | Merrimack Pharmaceuticals intends to declare $15.10 dividend |
Das Unternehmen HARMONY BIOSCIENCES HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 31,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
